Posted inCardiology Diabetes & Endocrinology news
Tirzepatide Produced Broad 72-Week Improvements in Cardiovascular Risk Biomarkers Across Inflammatory, Metabolic, Endothelial, and Thrombotic Pathways in Obesity
In a SURMOUNT-1 post hoc analysis, tirzepatide improved multiple cardiovascular risk biomarkers over 72 weeks in obesity, with the largest and most consistent effects seen for inflammation, insulin resistance, adiposity-related markers, endothelial dysfunction, and fibrinolytic balance.